ArticleHereditary cancer in clinical practice2019
Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report.
Abstract read
In one paragraph
Article in Hereditary cancer in clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Transitioning from the Prospective Lynch Syndrome Database (PLSD) to the International Lynch Syndrome Database (ILSD).Familial cancer · 2026Article
- From theory to practice: improving Lynch syndrome recognition through evidence-based education.Familial cancer · 2026Review
- Metachronous colorectal cancer risks after extended or segmental resection in MLH1, MSH2, and MSH6 Lynch syndrome: multicentre study from the Prospective Lynch Syndrome Database.The British journal of surgery · 2025Article
- Article
- Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome.JCO precision oncology · 2024Article
- Incidences of colorectal adenomas and cancers under colonoscopy surveillance suggest an accelerated "Big Bang" pathway to CRC in three of the four Lynch syndromes.Hereditary cancer in clinical practice · 2024Article
- Dominantly inherited micro-satellite instable cancer - the four Lynch syndromes - an EHTG, PLSD position statement.Hereditary cancer in clinical practice · 2023Review
- Balancing the burden and benefits of colonoscopy in Lynch Syndrome.Familial cancer · 2023Article
- Review
- Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium.Hereditary cancer in clinical practice · 2022Article
- Modifier genes and Lynch syndrome: some considerations.Hereditary cancer in clinical practice · 2022Review
- Progress Report: New insights into the prevention of CRC by colonoscopic surveillance in Lynch syndrome.Familial cancer · 2022Review
- Colorectal cancer in adolescents and young adults with Lynch syndrome: a Danish register-based study.BMJ open · 2021Article
- Immunoprofiles and DNA Methylation of Inflammatory Marker Genes in Ulcerative Colitis-Associated Colorectal Tumorigenesis.Biomolecules · 2021Article
- Immunology of Lynch Syndrome.Current oncology reports · 2021Review
- Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance.Journal of clinical medicine · 2021Article
- COVID-19 Disruptions to Endoscopic Surveillance in Lynch Syndrome.Cancer prevention research (Philadelphia, Pa.) · 2021Article
- Letter to the Editor-Recent advances in Lynch syndrome: response to Møller et al.Familial cancer · 2021Article
- Comparison of long-term outcomes between Lynch sydrome and sporadic colorectal cancer: a propensity score matching analysis.BMC cancer · 2021Article
- Prospective observational data informs understanding and future management of Lynch syndrome: insights from the Prospective Lynch Syndrome Database (PLSD).Familial cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors.
Mev Dominguez-Valentin *1Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-7856-0057
Toni T Seppälä *2Department of Gastrointestinal Surgery, Helsinki University Central Hospital, Helsinki, Finland.
Julian R Sampson4Division of Cancer and Genetics, Institute of Medical Genetics, Cardiff University School of Medicine, Cardiff, UK.
Finlay Macrae5The Royal Melbourne Hospital, Melbourne, Australia.
Ingrid Winship5The Royal Melbourne Hospital, Melbourne, Australia.
D Gareth Evans7University of Manchester & Manchester University Hospitals Foundation Trust, Manchester, UK.
Rodney J ScottUniversity of Newcastle and the Hunter Medical Research Institute, Callaghan, Australia.
John Burn9University of Newcastle, Newcastle upon Tyne, UK.
Gabriela Möslein10University Witten-Herdecke, Wuppertal, Germany.
Inge Bernstein11Department of Surgical Gastroenterology, Aalborg University Hospital, Aalborg, Denmark.
Kirsi Pylvänäinen12Central Finland Central Hospital, Education and Research, Jyväskylä, Finland.
Laura Renkonen-Sinisalo2Department of Gastrointestinal Surgery, Helsinki University Central Hospital, Helsinki, Finland.
Anna Lepistö2Department of Gastrointestinal Surgery, Helsinki University Central Hospital, Helsinki, Finland.
Annika Lindblom14Karolinska Institutet, Stockholm, Sweden.
John-Paul Plazzer5The Royal Melbourne Hospital, Melbourne, Australia.
Douglas Tjandra6University of Melbourne, Melbourne, Australia.
Huw Thomas15St Mark's Hospital, Department of Surgery and Cancer, Imperial College London, London, UK.
Kate Green7University of Manchester & Manchester University Hospitals Foundation Trust, Manchester, UK.
Fiona Lalloo7University of Manchester & Manchester University Hospitals Foundation Trust, Manchester, UK.
Emma J Crosbie16University of Manchester and St Mary's Hospital, Manchester, UK.
James Hill7University of Manchester & Manchester University Hospitals Foundation Trust, Manchester, UK.
Gabriel Capella17Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L'Hospitalet de Llobregat, Barcelona, Spain.
Marta Pineda17Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L'Hospitalet de Llobregat, Barcelona, Spain.
Matilde Navarro17Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L'Hospitalet de Llobregat, Barcelona, Spain.
Joan Brunet Vidal17Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L'Hospitalet de Llobregat, Barcelona, Spain.
Karina Rønlund19Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark.
Randi Thyregaard Nielsen20Department of Surgery, Regional Hospital West Jutland, Egtved, Denmark.
Mette Yilmaz21Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
Louise Laurberg Elvang22Department of Pathology, Herlev Gentofte University Hospital, Herlev, Denmark.
Lior Katz23High Risk and GI Cancer prevention Clinic, Gatro-Oncology Unit, The Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel.
Maartje Nielsen24Leids Universitair Medisch Centrum, Leiden, Netherlands.
Sanne W Ten Broeke24Leids Universitair Medisch Centrum, Leiden, Netherlands.
Sigve Nakken1Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.
Eivind Hovig1Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.
Lone Sunde26Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
Matthias Kloor27Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Magnus V Knebel Doeberitz27Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Aysel Ahadova27Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Noralane Lindor29Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ USA.
Verena Steinke-Lange30Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany.
Elke Holinski-Feder30Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany.
Jukka-Pekka Mecklin32Department of Surgery, Central Finland Central Hospital, Jyväskylä, Finland.
Pål Møller1Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.
Funding
Department of Health NIHR-CS-012-009Medical Research Council G0100496
Abstract
backgroundWe previously reported that in pathogenic mismatch repair (
methodsThe Prospective Lynch Syndrome Database (PLSD) that records outcomes of surveillance was examined to determine survival after colon cancer in relation to the time since previous colonoscopy and pathological stage. Only
resultsNinety-nine
conclusionsIn
Indexed as
Cancer stageColon cancerColonoscopyLynch syndromeSurveillanceSurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.